Oral Tadalafil in Children with Pulmonary Arterial Hypertension

Abstract

Objective: Tadalafil is a selective Phosphodiesterase-5 inhibitor that has been reported to have vasodilatory and antiproliferative effects on the pulmonary artery. In this study we evaluated the safety and efficacy of oral tadalafil in children with pulmonary arterial hypertension (PAH).

Methods: This open label study, prospective and interventional was carried out in 25 known patients aged 2 month–5 years in 3 medical centers in Iran, between March 2013–Jun 2014. Tadalafil suspension was administrated at 1 mg/kg daily for all patients. Hemodynamic and safety parameters were assessed at baseline and then monthly for a total of 4 visits.

Results: 19 patients received tadalafil as initial therapy, in all visits significant improvements in mean pulmonary arterial pressure were observed (p<0.01). Of the 25 patients, 6 (24%) had been on sildenafil for longer than 6 months. After transition from sildenafil to tadalafil clinical improvement was noted (p<0.05). Administration of tadalafil suspension was generally safe and well tolerated. Nausea was the most frequently reported adverse events which occurred in 3 patients during treatment.

Conclusions: Oral tadalafil was administered easily and tolerated well and improved mean pulmonary artery pressure (MPAP) in children with PAH, which suggests that oral tadalafil may be more effective and safer than sildenafil in the treatment of PAH.

Key words

children - pulmonary arterial hypertension - phosphodiesterase type 5 (PDE-5) inhibitor - tadalafil

• References

• 1 Simonneau G, Galie N, Rubin LJ et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43 (Suppl. 12) 5S-12S
• 2 Rubin LJ. Primary pulmonary hypertension. N Engl J Med 336 1997; 111-117
• 3 Barst RJ, McGoon M, Torbicki A et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004 43 (Suppl. 12) 40S-47S
• 4 McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation 2006; 114: 1417-1431
• 5 McLaughlin VV, Archer SL, Badesch DB et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009; 119: 2250-2294
• 6 Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004; 351: 1655-1665
• 7 Wharton J, Strange JW, Moller GM et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 2005; 172: 105-113
• 8 Ghofrani HA, Pepke-Zaba J, Barbera JA et al. Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43 (Suppl. 12) 68S-72S
• 9 FDA Approves Tadalafil for Pulmonary Hypertension (2009) Food and Drug Administration Web site. http://www.fdanews.com/articles/117688-fda-approves-tadalafil-for-pulmonary-hypertension Accessed 16 September 2013
• 10 Schulze-Neick I, Hartenstein P, Li J et al. Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease. Circulation 2003; 108 (Suppl. 01) II167-II173
• 11 Baquero H, Soliz A, Neira F et al. Oral Sildenafil in Infants With Persistent Pulmonary Hypertension of the Newborn: A Pilot Randomized Blinded Study. Pediatrics 2006; 117: 1077-1083
• 12 Abrams D, Schulze-Neick I, Magee AG. Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 2000; 84: E4
• 13 Barst RJ, Ivy DD, Gaitan G et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naïve children with pulmonary arterial hypertension. Circulation 2012; 125: 324-334
• 14 U.S. Food and Drug Administration (2012) FDA recommends against use of Revatio (sildenafil) in children with pulmonary hypertension. http://www.fda.gov/Drugs/DrugSafety/ucm317123.htm Accessed 16 September 2013
• 15 FDA Drug Safety Communication (2014) FDA clarifies Warning about Pediatric Use of Revatio (sildenafil) for Pulmonary Arterial Hypertension. http://www.fda.gov/Drugs/DrugSafety/ucm390876 Accessed 12 June 2014
• 16 Palmieri EA, Affuso F, Fazio S et al. Tadalafil in primary pulmonary arterial hypertension. Ann Intern Med 2004; 141: 743-744
• 17 Galiè N, Brundage BH, Ghofrani HA et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119: 2894
• 18 Ghofrani HA, Voswinckel R, Reichenberger F et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension. J Am Coll Cardiol 2004; 44: 1488-1496
• 19 Zhuang Y, Jiang B, Gao H et al. Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension. Hypertens Res 2014; 37: 507-512
• 20 Takatsuki S, Calderbank M, Ivy DD. Initial experience with Tadalafil in Pediatric Pulmonary Arterial Hypertension. Pediatr Cardiol 2012; 33: 683-688
• 21 Shlobin OA, Whitney Brown A, Weir N et al. Transition of PH patients from sildenafil to tadalafil: Feasibility and practical considerations. Lung 2012; 190: 573-578
• 22 Shapiro S, Traiger G, Hill W et al. Safety, tolerability, and efficacy of overnight switching from sildenafil to tadalafil in patients with pulmonary arterial hypertension. Cardiovasc Ther 2013; 31: 274-279
• 23 Sabri MR, Beheshtian E. Comparison of the Therapeutic and Side Effects of Tadalafil and Sildenafil in Children and Adolescents with Pulmonary Arterial Hypertension. Pediatr Cardiol 2014; 35: 699-704